Lung Surfactants: Treating Neonatal Respiratory Distress

Exogenous lung surfactant treats neonatal respiratory distress syndrome, a condition of premature neonates who lack sufficient surfactant to keep their alveoli open. Surfactant is delivered directly into the lungs to restore alveolar stability and improve gas exchange. The nurse must know its unique route, the rules that protect its effect, and the rapid physiologic changes it produces, because safe administration and monitoring determine the neonate's outcome. Surfactant is distinct among neonatal medications: it is given intratracheally, and it works within minutes, so lung compliance can improve quickly enough to require prompt ventilator adjustment. Protecting the freshly instilled drug from removal is essential to its success. Consider a case: you are the nurse caring for a premature neonate who received intratracheal surfactant 30 minutes ago and now has thick secretions, and a colleague suggests suctioning the airway. Which action is correct? You explain that suctioning is withheld for at least two hours after administration, because suctioning would remove the surfactant before it distributes and integrates into the alveolar lining, and you continue close respiratory monitoring while anticipating that improving compliance may...